Wells Fargo initiated coverage of Relay Therapeutics (RLAY) with an Equal Weight rating and $4 price target The firm likes Relay’s lead program RLY-2608, but thinks upside for shares may prove difficult as Wells sees a lack of near-term catalysts. While shares are cheap, the firm would wait before stepping in.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Strategic Operational Changes and Financial Stability Bolster Relay Therapeutics’ Buy Rating
- Relay Therapeutics weakness brings buying opportunity, says Barclays
- Relay Therapeutics: Promising Clinical Trials and Strategic Positioning Justify Buy Rating
- Buy Rating for Relay Therapeutics Amid Strategic Clinical Progress and Resource Optimization
- Relay Therapeutics price target lowered to $12 from $21 at Citizens JMP